Summary of Investments Made

$65.5M
Total to date

By Funding Area – In $Millions

$17.4
Discovery
$39.4
Clinical
$0.1
Manufacturing
$0
Introduction and Delivery
$8.7
Real World Evidence and Data Platforms
$0
Diagnostics

Clinical Investments

Filter Investments:
Sort by:
Use Case
Title
Description

Use Case: Pre-exposure Prophylaxis

Title: Henry Ford Health System WHIP Trial

Description:

Started early April in Michigan and Ohio and will target 3,000 health workers and first responders using hydroxychloroquine as pre-exposure prophylaxis. Currently at ~20% enrollment. 

Use Case: Pre-exposure Prophylaxis

Title: University of Oxford / Mahidol Oxford Tropical Medicine Research Unit (MORU) COPCOV Trial

Description:

Began at the end of March and uses hydroxychloroquine and chloroquine as pre-exposure prophylaxis. This will target 40,000 health workers, hospital inpatients and inpatient relatives who may become exposed to COVID-19. Interim read-out expected in fall 2020.  

Use Case: Pre-exposure Prophylaxis

Title: Washington University of St. Louis CROWN CORONATION Trial

Description:

Trial in re-planning phase, will commence in late summer in four African countries, UK, and US. The study seeks to target 55,000 health workers with the intent to test new regimens as pre-exposure prophylaxis. 

Use Case: Post-exposure Prophylaxis

Title: University of Washington: Post-exposure Prophylaxis Using Hydroxychloroquine

Description:

Began at the end of March and is targeting 2,000 close contacts of COVID-19 patients using hydroxychloroquine as post-exposure prophylaxis, currently at ~35% enrollment.  

Use Case: Prophylaxis

Title: Prophylaxis Registry Trial in Low and Middle-income Countries

Description:

Seeks to collect real-world evidence by capturing health workers’ self-initiated prophylaxis treatments and outcomes. The goal is to cover 10,000 health workers in six low- and middle-income country (LMIC) sites.  

Use Case: Mild Disease Treatment

Title: Medicines for Malaria Ventures ReACT trial

Description:

Exploratory study to be conducted in South Africa using five different experimental treatment arms versus standard of care for the treatment of COVID-19 infection in symptomatic outpatients with mild disease at the time of enrollment. 

Use Case: Mild Disease Treatment

Title: Montreal Heart Institute COLCORONA Trial: Mild Disease Treatment Using Colchicine

Description:

Started in March in Quebec and has since expanded to Spain, New York and California. This trial is targeting 6,000 outpatients using Colchicine to treat mild COVID-19. Given positive interim read-outs in June, this trial will continue to expand. ~25% enrollment completed.  

Use Case: Mild Disease Treatment

Title: University of Washington high risk outpatient trial

Description:

Targets high-risk patients in the outpatient setting using hydroxychloroquine, hydroxychloroquine + azithromycin, and Kaletra to treat mild COVID-19. This trial started mid-April at the University of Washington.  

Use Case: Moderate Disease Treatment

Title: University of Minnesota inpatient study

Description:

Includes a small group of 220 patients early in hospitalization in Cincinnati, Minnesota and Gainsville. This trial started at the end of April and is using Losartan to treat moderate COVID-19 and prevent progression. Expanding recruitment to 10 sites, this trial has achieved ~40% enrollment thus far.